Phenylketonuria: 2026 so far

Moved from head-to-head trial data to early real-world outcomes.

In the months covered, evidence on sepiapterin expanded from controlled phase 3 trials (a late-stage trial testing effectiveness and safety) to early real-world reports and a small report on adult functioning. A phase 3 randomized crossover trial found sepiapterin lowered blood Phe more than sapropterin over weeks 3-4. A phase 3 summary also reported Phe lowering versus placebo and sapropterin, including in classic PKU and in people described as unlikely to respond to older BH4-based treatment. A single-center retrospective review (a look back at clinic charts) reported many responders and frequent diet liberalization, with mainly gastrointestinal side effects and some stopping for inadequate response. A small 8-adult report linked Phe reductions with better self-reported day-to-day functioning for some, with variable side effects. In these reports, sepiapterin was repeatedly linked with lower Phe and, for some people, a higher dietary Phe allowance or better day-to-day functioning, but both response and tolerability differed from person to person.

Research covered in: January 2026, June 2026, September 2026

More detail emerged on persistence, side effects, and restarts.

In the available months, pegvaliase reports repeatedly described substantial Phe lowering alongside frequent side effects and real-world challenges with staying on treatment. A teen/young-adult chart review found average Phe decreased after starting pegvaliase, but injection site reactions, joint pain, and rash were common. Discontinuation was also reported, especially during late-adolescent school transitions. Real-world adult/adolescent reports described many people reaching Phe below 360 umol/L after months and often liberalizing diet. These reports also described very common side effects, including anaphylaxis (a severe allergic reaction) events in one dataset (none requiring hospitalization there) and one pegvaliase-related serious event (allergic arthritis) in a small Japanese follow-up. An advisory-board case review suggested many adults restarting pegvaliase again achieved Phe at or below 360 umol/L, with adverse events described as milder than during initial treatment. Overall, these reports linked pegvaliase with major Phe reductions and diet liberalization for many people, while also showing that side effects and life-stage pressures often influenced whether treatment could be continued.

Research covered in: February 2026, April 2026, June 2026, August 2026

Reports increasingly detailed social burden, caregiver strain, and supply gaps.

In the months covered, several studies described why PKU dietary treatment can be difficult to sustain. Reported reasons included social burden, fatigue and stress, caregiver strain, and system-level barriers to getting needed products. Adult surveys and cross-sectional studies (a snapshot at one point in time) reported stress about eating outside the home, fatigue, worse self-rated mental and general health, and lower diet-related quality of life when daily burden was higher. A screening study in teens/adults on prescription diets for inborn errors of metabolism (mostly PKU) found about one third screened positive on an eating-disorder questionnaire (screening, not diagnosis). Access and affordability were raised repeatedly. A Brazilian national survey covering diet-treated inborn errors of metabolism, mainly PKU and related disorders, described high costs, food insecurity, and supply problems for metabolic formula and low-protein foods. UK surveys in September described frequent disruptions in protein substitutes and special low-protein foods linked to GP prescribing and supply steps. These reports describe a situation where, even when someone understands the diet plan, the real-world workload and the reliability of supplies can directly affect how consistently dietary treatment can be followed.

Research covered in: February 2026, April 2026, June 2026, September 2026

Short trials tested timing and slow-release formats for substitutes.

A set of small studies looked at whether changing the type or timing of protein substitutes could improve Phe patterns. Other work described how everyday eating behaviors relate to out-of-range Phe. In children, an evening prolonged-release amino acid substitute lowered early-morning Phe versus a standard substitute in a short crossover period. In adolescents/adults, a prolonged-release substitute taken three times daily slightly lowered average 24-hour Phe and increased tyrosine (an amino acid made from Phe) over two-day test periods. A small pilot suggested a slow-release microtablet substitute was tolerated and used at least as well as usual substitutes over short follow-up. A child study linked higher Phe most strongly to eating higher-protein foods, with appetite and social difficulties more common when levels were uncontrolled. In these studies, some substitute formats or timing were linked with modest short-term improvements in Phe/tyrosine patterns, but the evidence is short-term and does not yet show longer-term functional benefits.

Research covered in: April 2026, July 2026, August 2026

Observational datasets highlighted adulthood and postpartum as vulnerable periods.

In routine-care datasets, Phe control was often described as better earlier in life and harder to maintain in adulthood. Pregnancy and postpartum showed a distinct pattern. UK center data reported that the share of Phe results in target ranges declined with age. More frequent Phe monitoring was linked with a higher proportion of results in range (association, not proof of causation). A European pregnancy cohort reported control improved during pregnancy (most measurements at or below 360 umol/L) and then worsened postpartum alongside reduced monitoring. A transition program reported Phe levels were similar before and after transfer to adult care, with many readings above 600 umol/L and many adults off-diet or reporting poor adherence. In these real-world datasets, major life transitions (moving to adult care, postpartum) and how often monitoring happened were repeatedly connected with how often Phe stayed within commonly used target ranges.

Research covered in: July 2026, September 2026